Notal Vision

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Notal Vision sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 10 completed top decile by trial count

Notal Vision: 11 sponsored US clinical trials, none currently recruiting.

Notal Vision sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. The most-studied condition in this pipeline is Diabetic Macular Edema, with 1 trials.

Top-decile sponsor footprint

Notal Vision ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

ACTIVE NOT RECRUITING

ForeseeHome NRich Registry

NCT05690880
COMPLETED

The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT

NCT05202587
COMPLETED

Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study

NCT05281042
COMPLETED

Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.

NCT04650672
COMPLETED

Single In-Clinic Encounter With the Notal Vision Home OCT

NCT04642183
COMPLETED

NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

NCT03969303
COMPLETED

Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration

NCT01334294
COMPLETED NA

HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device

NCT01103505
COMPLETED

Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment

NCT01083147
COMPLETED

Testing the Effectiveness of the Interactive Tutorial of the Home Macular Perimeter (HMP)

NCT00603850
COMPLETED

Sensitivity of the Home Macular Perimeter (HMP)

NCT00604071

Therapeutic Areas

Diabetic Macular Edema 1
AMD - Age-Related Macular Degeneration 1
Age-related Macular Degeneration 1

How the Notal Vision archive is shaped

11 indexed studies, none listed as recruiting (0% open); 10 completed (91%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Diabetic Macular Edema (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Notal Vision: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Notal Vision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Notal VisionAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Notal Vision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Notal Vision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Notal Vision page

11 registered trials is a research-attention snapshot, not an endorsement of Notal Vision or any single study.

  • None of Notal Vision's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Diabetic Macular Edema is the condition Notal Vision studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Macular Edema trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Notal Vision pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.